Delving into the Latest Updates on Human apotransferrin(Prothya Biosolutions) with Synapse

Overview

Basic Info

Drug Type

Protein drugs

Synonyms-

Target

TFR2 x TfR1

Action

agonists, stimulants

Mechanism

TFR2 agonists(transferrin receptor 2 agonists), TfR1 stimulants(Transferrin receptor protein 1 stimulants)

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Congenital Atransferrinemia

Inactive Indication

Beta-Thalassemia

Originator Organization

Prothya Biosolutions Netherlands B.V.

Active Organization

Prothya Biosolutions Netherlands B.V.

Inactive Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

RegulationOrphan Drug (European Union)

Login to view timeline

The purpose of this study is to establish the safety of the combined drug approach (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta, C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce ischemia-reperfusion injury during liver transplantation in eligible recipients.

Start Date01 Aug 2013

Sponsor / Collaborator-

NCT01797055

/ Active, not recruitingPhase 2/3

Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients

Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin replacement therapy in atransferrinemia patients.

Start Date01 Dec 2010

Sponsor / Collaborator

Prothya Biosolutions Netherlands B.V.

100 Clinical Results associated with Human apotransferrin(Prothya Biosolutions)

Login to view more data

100 Translational Medicine associated with Human apotransferrin(Prothya Biosolutions)

Login to view more data

100 Patents (Medical) associated with Human apotransferrin(Prothya Biosolutions)

Login to view more data

3

Literatures (Medical) associated with Human apotransferrin(Prothya Biosolutions)

01 Dec 2005·Veterinary RecordQ3 · AGRICULTURAL & FORESTRY SCIENCE

Effect of insulin on the proliferation of and progesterone production by buffalo granulosa cells in vitro

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Bhushan, S. ; Palta, P. ; Bansal, N. ; Sharma, V. ; Manik, R. S.

THE growth of ovarian follicles is a highly complex physiological process that is under the endocrine control of pituitary gonadotropins and is also regulated through paracrine and autocrine mechanisms by various hormones, growth factors and steroids. Much information is available about the growth and development of follicles from the primordial to the preovulatory stage in cattle (Driancourt 2001). Some information is now available, although in a fragmented form, on some of the major events of folliculogenesis in buffaloes (Bubalus bubalis) (Manik and others 2002), but information on the factors and mechanisms involved in regulating folliculogenesis is almost completely lacking in the species. As well as its known metabolic effects, insulin is involved in the regulation of ovarian function (Poretsky and Kalin 1987). Insulin has been shown to stimulate proliferation of and hormone production by ovarian granulosa cells in many species. However, the responsiveness of granulosa cells to insulin varies widely between species (Langhout and others 1991, Spicer and others 1993, Campbell and others 1996). No information is available on the concentrations of insulin that are effective in stimulating cell proliferation or hormone production by buffalo granulosa cells. This short communication describes a study to determine the effects of insulin on cell proliferation and progesterone production by buffalo ovarian granulosa cells cultured in vitro. Buffalo ovaries were collected from an abattoir immediately after slaughter, and washed three times with chilled (4 to 10°C) isotonic 0·9 per cent saline containing 400 iu/ml penicillin and 50 μg/ml streptomycin. All chemicals and media were purchased from Sigma unless otherwise indicated. After transport to the laboratory (within five to six hours, in chilled saline), the ovaries were immersed in 70 per cent ethanol for 30 seconds and then washed three times with saline at room temperature; henceforth, the ovaries were kept at room temperature. Granulosa cells were aspirated from small follicles (≤5 mm diameter, based on the surface diameter) with a 26 gauge needle attached to a 5 ml syringe and were washed three times with washing medium, which consisted of serum-free medium (DMEM:nutrient mixture F-12 Ham [1:1 ratio] supplemented with L-glutamine at a concentration recommended by the manufacturer, 5 μg/ml human apotransferrin, 0·1 per cent [w/v] bovine serum albumin, 10–7M androstenedione, 100 iu/ml penicillin, 0·1 mg/ml streptomycin and 0·25 μg/ml amphotericin B) plus 10 per cent fetal bovine serum (FBS). At each wash, the cells were separated by centrifugation at 200 g for 15 minutes. The pellet was resuspended in washing medium and was then passed through a 30 gauge needle attached to a 5 ml syringe to break up clumps of granulosa cells. The cells thus obtained were primarily antral (luminal) granulosa cells. The proportion of viable cells among the granulosa cells collected was determined by the trypan blue exclusion method using a haemocytometer. Granulosa cells were cultured in 48-well tissue culture plates in which the wells had been treated for optimal cell growth and attachment (one wash), at approximately 2 x105 viable cells in 500 μl of medium, for up to six days at 37°C in an atmosphere containing 5 per cent carbon dioxide. After 24 hours of culture, 250 μl of the medium in each well was replaced with an equal amount of fresh medium. The serumfree medium was supplemented with 10 per cent FBS for the first two days of culture to obtain optimal attachment of the cells. After this, the medium was completely removed and the attached cells in each well were washed twice with 300 μl serum-free medium. Incubations were then continued for another two or four days in 500 μl serum-free medium containing different concentrations of insulin (0, 10, 50, 100, 500 or 1000 ng/ml). The medium containing insulin was replaced daily with fresh medium containing the respective concentration of insulin. The samples of medium collected were stored at –20°C until subsequent analysis for progesterone. The experiment was concluded in some plates on day 4, whereas in the rest of the plates insulin treatment was continued up to day 6. The numbers of granulosa cells were determined at the end of the culture by a modification of a colorimetric method (Brasaemle and Attie 1988). After termination of the experiment, the microwells containing attached granulosa cells were rinsed twice with distilled water, and the cells were then fixed by the addition of 200 μl methanol per well and incubation at room temperature for 15 minutes. The plates were then emptied and completely dried. The cells were stained by the addition of 0·1 per cent (w/v) crystal violet and incubated at room temperature for 15 minutes. The plates were then emptied by inversion on to absorbent paper. The fixed, stained cells were solubilised by the addition of 2 per cent sodium deoxycholate (200 μl/well) and incubated at 60°C for one hour. The absorbance of the suspension in each well was read at 600 nm using a Beckman DU-640 spectrophotometer. The standard curve plotted between the number of cells and absorbance was linear between 103 and 105 cells. Veterinary Record (2005) 157, 746-748

01 Nov 2002·British Journal of HaematologyQ2 · MEDICINE

Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients

Q2 · MEDICINE

Article

Author: Leila Sahlstedt ; Tapani Ruutu ; Freja Ebeling ; Jaakko Parkkinen ; Leni Von Bonsdorff

Summary. Myeloablative treatment results in iron accumulation and the appearance of non‐transferrin‐bound iron (NTBI) in the circulation, which may contribute to treatment‐related organ damage and susceptibility to infections. The aim of this study was to investigate the efficacy of human apotransferrin in the binding of NTBI in patients receiving an allogeneic stem cell transplant after myeloablative conditioning. A single intravenous 100 mg/kg dose of apotransferrin was given to six adult patients on d 3 after the transplantation. Initially, all patients had serum transferrin saturation above 80% and NTBI in their serum. After the apotransferrin injection, serum NTBI became undetectable in all patients and transferrin saturation decreased to 30–50%. Serum transferrin increased by an average of 1·95 g/l. The administered apotransferrin was subsequently converted into monoferric and diferric transferrin forms. NTBI reappeared and transferrin saturation again exceeded 80% 12–48 h after the injection in four patients and after 6 d in one patient. NTBI remained non‐detectable for the whole 12 d follow‐up period in one patient. The apotransferrin injection was well tolerated and no adverse events with probable association with the apotransferrin were observed. Repeated apotransferrin infusions might completely eliminate NTBI and iron‐induced toxicity during myeloablative therapy.

Haematologica

Safety and efficacy of human apotransferrin infusion in patients with β-thalassemia intermedia: the AIM study

Article

Author: Nur, Erfan ; Konté, Kadère ; Budde, Ilona Kleine ; Biemond, Bart J. ; Swinkels, Dorine W ; Swinkels, Dorine W. ; Biemond, Bart J

Not available.

100 Deals associated with Human apotransferrin(Prothya Biosolutions)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Beta-Thalassemia	Phase 3	Netherlands	Prothya Biosolutions Netherlands B.V.	21 Mar 2019
Congenital Atransferrinemia	Phase 3	Germany	Prothya Biosolutions Netherlands B.V.	01 Dec 2010
Congenital Atransferrinemia	Phase 3	Italy	Prothya Biosolutions Netherlands B.V.	01 Dec 2010
Congenital Atransferrinemia	Phase 3	Spain	Prothya Biosolutions Netherlands B.V.	01 Dec 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2024	Phase 2/3	Congenital Atransferrinemia	5	Human Apotransferrin	pkxhvlycxi(ofaghuoqax) = slightly lower than the mean dose-normalized AUC∞ at a single dose in year 1, indicating non-linearity uqdlgvhqsn (hwyoxwfclh ) View more	Positive	14 May 2024
EHA2024	Phase 2/3	Congenital Atransferrinemia	5	Human Apotransferrin (Control (No Treatment))		Positive	14 May 2024
ASH2023	Phase 2/3	Congenital Atransferrinemia	5	Human apotransferrin	ororcteofu(pzlipoigso) = wyokovcoky ntclgrqgds (aexegnxmym )	Positive	11 Dec 2023

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data